

Indonesia Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Indonesia			
2. Grant number: 17-IDN-32a-Y; 18-IDN-32a-Y			
3. Date of Decision Letter: 29 June 2018			
4. Date of the Partnership Framework Agreement: December 2014			
5. Programme title: Injection safety devices ¹			
6. Programme duration²: 2017-2018			
7. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2017	2018	Total ³
Programme Budget (US\$)	163,500	183,000	346,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
TOTAL injection safety devices to be purchased with Gavi funds in each year	2017	2018	2019
Number of AD syringes	3,234,400	4,039,000	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	35,600	44,450	-
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)	163,500	183,000	-
Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u>			
New Vaccine Support (NVS), HPV /Quadrivalent, 1 dose(s) per vial, LIQUID, Demonstration	2018	2019	
Number of AD syringes	20,100		

¹ This does not include vaccines.


² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

Number of re-constitution syringes	-	
Number of safety boxes	225	
Annual Amounts for injection safety devices for Vaccine (US\$)	1,000	
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, Routine	2018	2019
Number of AD syringes	4,018,900	
Number of re-constitution syringes	-	
Number of safety boxes	44,225	
Annual Amounts for injection safety devices for Vaccine (US\$)	182,000	
9. Procurement agency: HPV: UNICEF IPV: Not applicable		
10. Self-procurement: HPV: Not applicable IPV: Self-procurement applies. Please refer to the partnership framework agreement terms and conditions.		
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.		

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
29 June 2018